1[1]Cook J. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vas Biol,2000;20:2032-2037
2[2]Jono S, Mckee M, Murry C, et al. Phosphate regulation of vascular smooth muscle cell calcification.Cirs Res,2000;87(7):E10-17
3[3]Fliser D, Kielstein J, Haller H, et al. Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Kidney Int,2003;63(suppl 84):pp.S37-S40
4[4]Zoccali C, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-2117
5[5]Lin K, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.Circulation,2002;106:987-992
6[6]Rostand S, Drueke T. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999 Aug;56(2):383-392
7[7]Gérard M,Sylvain J, Marchais A, et al. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int,2003;63(suppl 84):pp.S88-S93
8[8]Misselwitz J, et al. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.Pediatr Nephrol,2002;17(5):316-321
9[9]Nakayama M, Kawaguchi Y, Yamada K, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int,1997;51:182-186
10[10]Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.Circulation,1998;20:138-140
